A 6-month Study to Evaluate Sulforaphane Effects in PD Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05084365 |
Recruitment Status :
Recruiting
First Posted : October 19, 2021
Last Update Posted : July 6, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Parkinson Disease | Drug: Sulforaphane Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A 6-month Study to Evaluate Sulforaphane Effects in Treatment of Cognition Impairment of PD Patients |
Actual Study Start Date : | November 28, 2021 |
Estimated Primary Completion Date : | November 15, 2023 |
Estimated Study Completion Date : | December 31, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: sulforaphane
The goal of the study is to investigate whether adding sulforaphane will benefit cognitive function in individuals who have PD.
|
Drug: Sulforaphane
Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants. |
Placebo Comparator: placebo
The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
|
Drug: Placebo
Placebo |
- Cognitive improvement assessed using the MATRICS Consensus Cognitive Battery (MCCB) composite score [ Time Frame: 24 weeks ]The investigators will use the MATRICS Consensus Cognitive Battery (MCCB) Composite score as primary cognitive outcome measure.The MCCB total score is about 50 in healthy participants, the higher the score, the better the cognition performance.
- Change of clinical symptoms by UPDRS [ Time Frame: 24 weeks ]The change of UPDRS(Unified Parkinson Disease Rating Scale),ranging from 0-199, higher scores mean a worse outcome.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age range from 40 to 75, regardless of ethnic group or gender;
- Meeting the criteria for clinically established PD (2015) by Movement Disorder Association(MDS); duration < 5 years;
- Mini-Mental State Examination (MMSE) ≤ 27 points, but ≥20 points. Hoehn-Yahr stage ≤ 3;
- Before enrollment, patients should take a stable dose of dopamine-based therapies drugs;
- No obvious visual or hearing impairment;
- More than 9 years of education;
- Patients understand and comply with the study procedure, and are able to complete all tests and examinations required by the program. Sign the informed consent.
Exclusion Criteria:
- Patients who have received globus pallidotomy, thalamotomy, deep brain stimulation (DBS), or stem cell therapy;
- Other causes of parkinsonism: medications (e.g., metoclopramide, flunarizine), metabolic neurogenetic disorders (e.g., Wilson's disease), encephalitis, cerebrovascular diseases, or degenerative disorders (e.g., progressive supranuclear palsy);
- Central nervous system diseases (including stroke, optic neuromyelitis, Parkinson's disease, epilepsy, etc.);
- Have liver, kidney function insufficiency;
- Unstable or severe diseases of the heart, lung, liver, kidney and hematopoietic system according to the judgment of the researchers;
- Participated in other clinical trials within 3 months before screening visit;
- Other conditions are unsuitable for participating in this study according to the judgement of researchers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05084365
Contact: Renrong Wu | +8615874179855 | wurenrong@csu.edu.cn | |
Contact: Hainan Zhang | +8613508474343 | yyzhn@sina.com |
China, Hunan | |
Mental Health Institute of Second Xiangya Hospital,CSU | Recruiting |
Changsha, Hunan, China, 410011 | |
Contact: Renrong Wu, PhD 15874179855 wurenrong2013@163.com |
Principal Investigator: | Renrong Wu | the Second Xiangya hospital, Central South University, 410011, Changsha, China. |
Responsible Party: | Renrong Wu, Professor, Central South University |
ClinicalTrials.gov Identifier: | NCT05084365 |
Other Study ID Numbers: |
PD-Sulforaphane |
First Posted: | October 19, 2021 Key Record Dates |
Last Update Posted: | July 6, 2023 |
Last Verified: | July 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Sulforaphane Parkinson's disease cognition |
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders |
Synucleinopathies Neurodegenerative Diseases Sulforaphane Anticarcinogenic Agents Protective Agents Physiological Effects of Drugs Antineoplastic Agents |